溶瘤腺病毒与抗癌药物联合治疗肝肿瘤的可行性研究

Feasibility Study of Oncolytic Adenoviral Vectors Combined with Chemotherapeutic Agents

通过抗肿瘤药物PHA-767491联合溶瘤腺病毒AdCN305-HcRed开展针对肝癌细胞系HepG2的杀伤效率研究。通过PHA-767491单独及其与AdCN305-HcRed联合共同杀伤肝癌细胞来探究细胞周期抑制性化疗药物与溶瘤腺病毒联合使用的可行性。细胞杀伤实验结果发现PHA-767491能抑制溶瘤腺病毒在肝肿瘤细胞HepG2内的增殖,从而影响溶瘤腺病毒的增殖溶瘤作用。结果表明:溶瘤腺病毒与抑制细胞周期的化疗药物联合在肝肿瘤中的应用需要慎重。

The present study means to probe whether oncolytic adenoviral vectors combined with chemotherapeutic agents can reach synergistic antitumor effects though a new antitumor small-molecule PHA- 767491 and oncolytic adenovirus AdCN305-HcRed. Altogether experiment results demonstrate that propa- gation of oncolytic adenovirus is inhibited and the combined killing-effects are not obtained. In a word, planning to use oncolytic adenovirus and cell cycle-arrested reagents should be carried out thoughtfully.